4D Molecular Therapeutics announced an acceleration in the timeline for its 4FRONT-1 Phase 3 trial data readout of the 4D-150 treatment for wet age-related macular degeneration (AMD), now expected in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback